We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.05P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.0525 | 84.00% | 0.115 | 169,133,452 | 16:29:08 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.105 | 0.125 | 0.1175 | 0.0625 | 0.0625 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | -859k | -0.0006 | -1.83 | 887.07k |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:43 | O | 3,546,558 | 0.112 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 13/1/2025 | 12:50 | ALNC |  TRADING UPDATES: Eden Research in revenue rise; Cordel gets UK deal |
| 13/1/2025 | 07:00 | UK RNS | Nuformix PLC NXP002 Orphan Drug Designation Draft Application |
| 29/11/2024 | 17:00 | UK RNS | Nuformix PLC Total Voting Rights |
| 05/11/2024 | 14:25 | UK RNS | Nuformix PLC Director/PDMR Dealings |
| 04/11/2024 | 10:17 | UK RNS | Nuformix PLC Result of General Meeting |
| 16/10/2024 | 12:37 | UK RNS | Nuformix PLC Publication of Prospectus & Notice of GM |
| 20/9/2024 | 13:24 | UK RNS | Nuformix PLC £300,000 Fundraise |
| 18/6/2024 | 17:37 | ALNC | IN BRIEF: Nuformix shares fall despite interim loss narrowing |
| 18/6/2024 | 06:00 | UK RNS | Nuformix PLC Half-year Report |
| 17/6/2024 | 09:37 | ALNC | Nuformix touts patent wins for idiopathic pulmonary fibrosis treatment |
Nuformix (NFX) Share Charts1 Year Nuformix Chart |
|
1 Month Nuformix Chart |
Intraday Nuformix Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/1/2025 | 18:04 | NUFORMIX September 2 Presentations - Massive Upside NFX | 721 |
| 18/5/2023 | 06:08 | Nuformix plc | 9,116 |
| 28/1/2021 | 15:43 | ****NFX2021**** | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:29:44 | 0.11 | 3,546,558 | 3,972.14 | O |
| 16:29:40 | 0.11 | 385,591 | 431.86 | O |
| 16:29:18 | 0.11 | 5,763,576 | 6,120.92 | O |
| 16:29:13 | 0.11 | 412,280 | 470.00 | O |
| 16:29:12 | 0.11 | 174,570 | 199.01 | O |
| Top Posts |
|---|
Posted at 27/1/2025 08:20 by Nuformix Daily Update Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.06p.Nuformix currently has 1,419,309,368 shares in issue. The market capitalisation of Nuformix is £1,561,240. Nuformix has a price to earnings ratio (PE ratio) of -1.83. This morning NFX shares opened at 0.06p |
Posted at 27/1/2025 16:39 by putinaire I dunno. But they will always motor on if the bid gets out after mid touching an important price |
Posted at 27/1/2025 12:05 by putinaire increased, to the dead zone. needs to be above it to show that anyone is allowed to make - and then know its not just a spike of right ask price |
Posted at 27/1/2025 11:38 by putinaire Not be a spike of a good price then |
Posted at 27/1/2025 10:47 by dicko80 Buy price now 0.0695 |
Posted at 20/1/2025 12:41 by putinaire Lets say i bought 20% higher than current price..Socio will probably say, 'you missed 20%' Not really. All the gamble phases i did not enter, they are down 90% on every one of em Sometimes you know, it's better to miss the odd one anyway. Far better than to gamble in many. Esp in UK where it's just a PI fodder market |
Posted at 20/1/2025 12:06 by putinaire Showing your amateurism. When news is due, its always in price days prior. Would buy in the range if saw that. But it aint there yet |
Posted at 20/1/2025 11:54 by putinaire Just in basic raw price terms, a breakout would be validated by DecemberDont think of it as price action example the shape of a candle lol. Its not what i look at , at all |
Posted at 19/1/2025 15:00 by dicko80 Let’s just be straight …$10bn sales by 2028 for their lynparza little old NFX NPX004 out performs Lynparza current mkt cap just £700k Make no bones about it .. AZ will not let NPX004 go anywhere else |
Posted at 13/1/2025 08:49 by putinaire Run along now chimpy's. We will all be back at a price that makes senseToodles P |
Posted at 14/12/2021 17:53 by sentiment riles Lanstead Investment – Q&AQ. Why did Nuformix choose the Sharing Agreements with Lanstead? A: The sharing agreements with Lanstead allows Nuformix to benefit from positive share price performance over 20 months and the funding supports Nuformix’s activities over that period. We see a number of positive catalysts for Nuformix over the coming months, in particular as we make NXP004 Phase 1 ready and continue to strengthen the IP around NXP004, which should be positive for the share price as these are announced. Q: Is Lanstead entitled to invest monthly at a fixed discount to the prevailing Nuformix share price from month-to-month? A: No. Lanstead will be issued and will immediately pay for the shares it subscribes for at 1.5p per share. The number of shares issued to Lanstead is fixed and does not change. However, the amount from Lanstead due to the Company under the sharing agreements is adjustable upwards or downwards at each of the 20 monthly settlements that follow. For example; the approximate amount in any particular month will be 10% more than £82,500 if the share price is 10% higher than the 2.0p benchmark price (“BMP”) or 10% less than £82,500 if the share price is 10% lower than the BMP. Q: Can Lanstead benefit by the share price being lower than the 2.0p BMP, rather than going higher than 2.0p? A: No. Lanstead makes more money the higher the share price is. Through the sharing agreements Lanstead shares some, but not all, of the upside when the share price appreciates with Nuformix. The sharing agreements are an incentive for Nuformix to perform, thereby benefitting all shareholders including Lanstead. If the share price over 20 months averages double the BMP (i.e. 4.0p) then the Company will receive double the initial Lanstead subscription of £1.65 million (i.e. £3.30 million instead of £1.65 million). If the share price over 20 months averages half the BMP (i.e. 1.0p) then the Company will ultimately receive half the initial Lanstead subscription (i.e. £0.825 million instead of £1.65 million). The projected outcome for Nuformix is contractually clear and the value of Lanstead’s investment is greater if the company’s share price is higher. It is important to note that Lanstead participates in the majority, but not all of the upside in any future Nuformix share price appreciation. The bottom line is that Lanstead makes more money as the share price rises and does not derive any advantage from a decline in the share price. Q: Can Lanstead trade its Nuformix shares? A: Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its investee companies. Like any institutional investor Lanstead only invests in companies where it can see strong potential for share price appreciation. Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead has an uncapped commitment through the sharing agreements to remit amounts each month to Nuformix based on the prevailing share price. Therefore whilst Lanstead may take a profit along the way (like any shareholder) and cover its downside risk on the investment (just like any shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant on-going shareholding because of its uncapped exposure on the amounts due to Nuformix over the 20 months of the sharing agreements should the Nuformix shares appreciate |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
